US Pharma MarketingThe biggest barrier for a top schzophrenia treatment, Ionis' first approval for Alexander disease, and more biotech news research FDA patients Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout FDA takes another look at botanical drugs The biggest barrier for a top schzophrenia treatment, Ionis’ first approval…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we look at the FDA’s interest in botanical drugs, the persistent barriers to clozapine use, and the ways in which pig kidneys could bridge patients to human transplants.
No better place than a SoCal gym to unfurl the mechanics of unapproved peptide trafficking. Trust me.
Source: STAT News Pharma